RxDoctor Payments Data

Walter Grote, DO

Internal Medicine · Sparta, NJNPI 1811983745

Payments from drug & device makers

$1,197in general payments, 2019–2025

Across 66 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$379
  • Amgen$249
  • AstraZeneca$193
  • Boehringer Ingelheim$94
  • Amarin Pharma, Inc.$71
  • Pfizer$33
  • plus $178 from 8 others

What the payments were for

  • Food & beverage$1,197100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,197 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$134,177
Medicare patients
122
Services billed
1,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$97,110
NuplazidPimavanserin Tartrate13$65,735
OxycontinOxycodone Hcl13$33,699
TrulicityDulaglutide18$32,235
JardianceEmpagliflozin29$30,696
FarxigaDapagliflozin Propanediol33$30,046
Breo ElliptaFluticasone/Vilanterol21$13,080
VascepaIcosapent Ethyl11$9,817
DapagliflozinDapagliflozin Propanediol12$8,057
Icosapent Ethyl15$5,527
CholestyramineCholestyramine (With Sugar)20$2,595
Colesevelam Hcl27$1,927
Levothyroxine Sodium120$1,548
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,392
Armour ThyroidThyroid,pork18$1,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$379$97,11084 claims
Lilly USA, LLCTrulicity$30$32,23518 claims
Boehringer IngelheimJardiance$94$30,69629 claims
AstraZenecaFarxiga$193$30,04633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Sparta

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →